New Cancer Drug Combination Shows Positive Results for Gastric Cancer Patients

Rhea-AI Filing Summary

I-MAB has announced positive Phase 1b dose escalation data for their drug candidate Givastomig in combination with immunochemotherapy for first-line treatment of gastric cancers. The results were presented at the ESMO GI 2025 conference.

This Form 6-K, filed by the Maryland-based biopharmaceutical company, includes an exhibit (99.1) containing the press release detailing the clinical trial outcomes. The filing was signed by Joseph Skelton, the company's Chief Financial Officer.

The filing indicates that I-MAB continues to file annual reports under Form 20-F as a foreign private issuer. This development represents a significant milestone in I-MAB's oncology pipeline, particularly in the gastric cancer treatment landscape.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-39173

I-MAB

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release - I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	I-MAB
	By	:	/s/ Joseph Skelton
	Name	:	Joseph Skelton
	Title	:	Chief Financial Officer

Date: June 26, 2025

FAQ

What clinical trial data did IMAB present at ESMO GI 2025?

According to the 6-K filing, I-MAB presented positive Phase 1b dose escalation data for Givastomig in combination with immunochemotherapy for first-line treatment of gastric cancers at the ESMO GI 2025 conference.

Who is the current CFO of IMAB as of June 2025?

According to the 6-K filing, Joseph Skelton is serving as the Chief Financial Officer of I-MAB, as evidenced by his signature on the document dated June 26, 2025.

What type of annual reports does IMAB file with the SEC?

The 6-K filing indicates that I-MAB files annual reports under Form 20-F, as shown by the checked box in the filing form, which is typical for foreign private issuers listed in the United States.

Where is IMAB's principal executive office located?

According to the 6-K filing, I-MAB's principal executive offices are located at 2440 Research Boulevard, Suite 400, Rockville, MD 20850.

What was the purpose of IMAB's June 2025 6-K filing?

The purpose of this 6-K filing was to report the presentation of clinical trial data, specifically positive Givastomig Phase 1b dose escalation data in combination with immunochemotherapy for first-line gastric cancer patients, which was presented at ESMO GI 2025.